Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE · NASDAQ Global Select
+$0.81 today
Vol 3.28M · Avg 1.81M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
-25.50%
Period High
$41.44
Period Low
$18.50
Latest
$27.44
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.42B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.38B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.08B
Celcuity Inc.
NASDAQ:CELC
$4.19B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.24B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.91B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ascentage Pharma Group International
NASDAQ:AAPG
$407.64M
What is the latest RARE filing?
The latest filing shown is 4 dated Jun 15, 2026.
How many recent filings does RARE have?
Intrinsic Alpha currently shows 20 recent filings for RARE.
Explore More
Continue the stock analysis
Jump to another research area for this company.